Design and characterization of polytope construct with multiple B and T H epitopes of Japanese encephalitis virus

Virus Research

Volumn 166, Issue 1-2, 2012, Pages 77-86

  Kulkarni, Reshma ^a   Sapkal, Gajanan ^a   Mahishi, Lata ^b   Shil, Pratip ^a   Gore, Milind M ^a  

^a NATIONAL INSTITUTE OF VIROLOGY   (India)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Envelope protein; Expression optimization; Japanese encephalitis virus; Polytope constructs; Protective immunity; Vaccine

Indexed keywords

EPITOPE; JAPANESE ENCEPHALITIS VACCINE; NEUTRALIZING ANTIBODY; NONSTRUCTURAL PROTEIN 1; POLYTOPE DNA CONSTRUCT; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DRUG DESIGN; DRUG RESPONSE; EPITOPE MAPPING; HELPER CELL; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; JAPANESE ENCEPHALITIS; JAPANESE ENCEPHALITIS VIRUS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ENCEPHALITIS VIRUS, JAPANESE; EPITOPES, B-LYMPHOCYTE; EPITOPES, T-LYMPHOCYTE; JAPANESE ENCEPHALITIS VACCINES; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

FLAVIVIRUS; JAPANESE ENCEPHALITIS VIRUS; MUS;

EID: 84860638115     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2012.03.006     Document Type: Article

References (80)

1. Ashok M.S., Rangarajan P.N. Immunization with plasmid DNA encoding the envelope glycoprotein of Japanese Encephalitis virus confers significant protection against intracerebral viral challenge without inducing detectable antiviral antibodies. Vaccine 1999, 18:68-75.
2. Ahsan M.F., Gore M.M. Comparison of immune response generated against Japanese encephalitis virus envelope protein expressed by DNA vaccines under macrophage associated versus ubiquitous expression promoters. Virol J. 2011, 8(1):382.
3. Alka, Bharati A.K., Malik Y.P., Vrati S. Immunogenicity and protective efficacy of the E. coli-expressed domain III of Japanese encephalitis virus envelope protein in mice. Med. Microbiol. Immunol. 2007, 196(4):227-231.
4. Arashkia A., Roohvand F., Memarnejadian A., Aghasadeghi M.R., Rafati S. Construction of HCV-polytope vaccine candidates harbouring immune-enhancer sequences and primary evaluation of their immunogenicity in BALB/c mice. Virus Genes 2010, 40(1):44-52.
5. Batra G., Nemani S.K., Tyagi P., Swaminathan S., Khanna N. Evaluation of envelope domain III-based single chimeric tetravalent antigen and monovalent antigen mixtures for the detection of anti-dengue antibodies in human sera. BMC Infect. Dis. 2011, 11:64-69.
6. Bazhan S.I., Belavin P.A., Seregin S.V., Danilyuk N.K., Babkina I.N., Karpenko L.I., Nekrasova N.A., Lebedev L.R., Ignatyev G.M., Agafonov A.P., Poryvaeva V.A., Aborneva I.V., Ilyichev A.A. Designing and engineering of DNA-vaccine construction encoding multiple CTL-epitopes of major HIV-1 antigens. Vaccine 2004, 22(13-14):1672-1682.
7. Bernardo L., Izquierdo A., Alvarez M., Rosario D., Prado I., López C., Martínez R., Castro J., Santana E., Hermida L., Guillen G., Guzmán M.G. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral. Res. 2008, 80(2):194-199.
8. Burke D.S., Lorsomrudee W., Leake C.J., Hoke C.H., Nisalak A., Chongswasdi V., Laorakpongse T. Fatal outcome in Japanese encephalitis. Am. J. Trop. Med. Hyg. 1985, 34(6):1203-1210.
9. Cecilia D., Gadkari D.A., Kedarnath N., Ghosh S.N. Epitope mapping of Japanese encephalitis virus envelope protein using monoclonal antibodies against an Indian strain. J. Gen. Virol. 1988, 69(Pt 11):2741-2747.
10. Chen S., Yu M., Jiang T., Deng Y., Qin C., Qin E. Induction of tetravalent protective immunity against four dengue serotypes by the tandem domain III of the envelope protein. DNA Cell Biol. 2007, 6:361-367.
11. Chu J.H., Chiang C.C., Ng M.L. Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection. J. Immunol. 2007, 178(5):2699-2705.
12. Coban C., Ishii K.J., Gursel M., Klinman D.M., Kumar N. Effect of plasmid backbone modification by different human CpG motifs on the immunogenicity of DNA vaccine vectors. J. Leukoc. Biol. 2005, 78(3):647-655.
13. Cui Z. DNA vaccine. Adv. Genet. 2005, 54:257-289.
14. Dewasthaly S., Ayachit V.M., Sarthi S.A., Gore M.M. Monoclonal antibody raised against envelope glycoprotein peptide neutralizes Japanese encephalitis virus. Arch. Virol. 2001, 146(7):1427-1435.
15. Dewasthaly S.S., Bhonde G.S., Shankarraman V., Biswas S.M., Ayachit V.M., Gore M.M. Chimeric T helper-B cell peptides induce protective response against Japanese encephalitis virus in mice. Protein Pept. Lett. 2007, 14(6):543-551.
16. Duraiswamy J., Bharadwaj M., Tellam J., Connolly G., Cooper L., Moss D., Thomson S., Yotnda P., Khanna R. Induction of therapeutic T-cell responses to subdominant tumor-associated viral oncogene after immunization with replication-incompetent polyepitope adenovirus vaccine. Cancer Res. 2004, 64(4):1483-1489.
17. Gangwar R.S., Shil P., Cherian S.S., Gore M.M. Delineation of an epitope on domain I of Japanese encephalitis virus Envelope glycoprotein using monoclonal antibodies. Virus Res. 2011, 158(1-2):179-187.
18. Gangwar R.S., Shil P., Sapkal G.N., Khan S.A., Gore M.M. Induction of virus-specific neutralizing immune response against West Nile and Japanese encephalitis viruses by chimeric peptides representing T-helper and B-cell epitopes. Virus Res. 2012, 163(1):40-50.
19. Ghochikyan A., Vasilevko V., Petrushina I., Movsesyan N., Babikyan D., Tian W., Sadzikava N., Ross T.M., Head E., Cribbs D.H., Agadjanyan M.G. Generation and characterization of the humoral immune response to DNA immunization with a chimeric beta-amyloid-interleukin-4 minigene. Eur. J. Immunol. 2003, 33(12):3232-3241.
20. Goncalvez A.P., Chien C.H., Tubthong K., Gorshkova I., Roll C., Donau O., Schuck P., Yoksan S., Wang S.D., Purcell R.H., Lai C.J. Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo. J. Virol. 2008, 82(14):7009-7021.
21. Gore, M.M., Kolaskar, A.S., Dewasthaly, S.S., Kulkarni-Kale, U.D., Sawant, S., 2008. Chimeric T helper-B cell peptide vaccine for Japanese encephalitis virus. Patent no.: US7 425,335 B2.
22. Guirakhoo F., Pugachev K., Zhang Z., Myers G., Levenbook I., Draper K., Lang J., Ocran S., Mitchell F., Parsons M., Brown N., Brandler S., Fournier C., Barrere B., Rizvi F., Travassos A., Nichols R., Trent D., Monath T. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J. Virol. 2004, 78(9):4761-4775.
23. Gupta A.K., Lad V.J., Koshy A.A. Protection of mice against experimental Japanese encephalitis virus infections by neutralizing anti-glycoprotein E monoclonal antibodies. Acta Virol. 2003, 47(3):141-145.
24. Gurunathan S., Klinman D.M., Seder R.A. DNA vaccines: immunology application, and optimization. Annu. Rev. Immunol. 2000, 18:927-974.
25. Halstead S.B., Tsai T.F. Japanese encephalitis vaccines. Vaccine 2004, 919-958. Elsevier Inc., USA. 4th ed. S.A. Plotkin, W.A. Orenstein (Eds.).
26. Halstead S.B., Thomas S.J. New Japanese encephalitis vaccines: alternatives to production in mouse brain. Expert Rev. Vaccines 2011, 10:355-364.
27. Hapugoda M.D., Batra G., Abeyewickreme W., Swaminathan S., Khanna N. Single antigen detects both immunoglobulin M (IgM) and IgG antibodies elicited by all four dengue virus serotypes. Clin. Vaccine Immunol. 2007, 14(11):1505-1514.
28. Hermida L., Bernardo L., Izquierdo A., Alvarez M., Rosario D., Prado I., López C., Martínez R., Castro J., Santana E., Guillen G., Guzmán M.G. Immunogenicity and protective efficacy of a recombinant fusion protein containing the domain III of the dengue 1 envelope protein in non-human primates. Antiviral Res. 2008, 80(2):194-199.
29. Hermida L., Bernardo L., Martín J., Alvarez M., Prado I., López C., Sierra Bde L., Martínez R., Rodríguez R., Zulueta A., Pérez A.B., Lazo L., Rosario D., Guillén G., Guzmán M.G. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 2006, 24(16):3165-3171.
30. Hombach J., Solomon T., Kurane I., Jacobson J., Wood D. Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004. Vaccine 2005, 23(45):5205-5211.
31. ®-a cell-derived inactivated vaccine for Japanese encephalitis. Virus Adapt. Treat. 2009, 1:11-22.
32. Kaur R., Vrati S. Development of a recombinant vaccine against Japanese encephalitis. J. Neurovirol. 2003, 9(4):421-431.
33. Kaur R., Sachdeva G., Vrati S. Plasmid DNA immunization against Japanese encephalitis virus: immunogenicity of membrane-anchored and secretory envelope protein. J. Infect. Dis. 2002, 185(1):1-12.
34. Kelley L.A., Sternberg M.J.E. Protein structure prediction on the web: a case study using the Phyre server. Nat. Protoc. 2009, 4:363-371.
35. Kimura-Kuroda J., Yasui K. Protection of mice against Japanese encephalitis virus by passive administration with monoclonal antibodies. J. Immunol. 1988, 141:3606-3610.
36. Klinman D.M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 2004, 4:249-258.
37. Klinman.D.M., Yamshchikov G., Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J. Immunol. 1997, 158(8):3635-3639.
38. Kojima Y., Xin K.Q., Ooki T., Hamajima K., Oikawa T., Shinoda K., Ozaki T., Hoshino Y., Jounai N., Nakazawa M., Klinman D., Okuda K. Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine. Vaccine 2002, 20(23-24):2857-2865.
39. Kolaskar A.S., Tongaonkar P.C. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett. 1990, 276(1-2):172-174.
40. Krieg A.M. Therapeutic potential of Toll-like receptor 9 activation. Nat. Rev. Drug Discov. 2006, 5(6):471-484.
41. Krishna V.D., Rangappa M., Satchidanandam V. Virus-specific cytolytic antibodies to nonstructural protein 1 of Japanese encephalitis virus effect reduction of virus output from infected cells. J. Virol. 2009, 83(10):4766-4777.
42. Kumar P., Krishna V.D., Sulochana P., Nirmala G., Haridattatreya M., Satchidanandam V. Cell-mediated immune responses in healthy children with a history of subclinical infection with Japanese encephalitis virus: analysis of CD4+ and CD8+ T cell target specificities by intracellular delivery of viral proteins using the human immunodeficiency virus Tat protein transduction domain. J. Gen. Virol. 2004, 85(2):471-482.
43. Kumar P., Sulochana P., Nirmala G., Chandrashekar R., Haridattatreya M., Satchidanandam V. Impaired T helper 1 function of nonstructural protein 3-specific T cells in Japanese patients with encephalitis with neurological sequelae. J. Infect. Dis. 2004, 189(5):880-891.
44. Kutubuddin M., Gore M.M., Banerjee K., Ghosh S.N., Kolaskar A.S. Analysis of computer-predicted antibody inducing epitope on Japanese encephalitis virus. Acta Virol. 1993, 37(6):417-428.
45. Kutubuddin M., Kolaskar A.S., Galande S., Gore M.M., Ghosh S.N., Banerjee K. Recognition of helper T cell epitopes in envelope (E) glycoprotein of Japanese encephalitis, west Nile and Dengue viruses. Mol. Immunol. 1991, 28(1-2):149-154.
46. Kutzler M.A., Weiner D.B. DNA vaccines: ready for prime time?. Nat. Rev. Genet. 2008, 9(10):776-788.
47. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. PROCHECK-a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 1993, 26:283-291.
48. Leng C.H., Liu S.J., Tsai J.P., Li Y.S., Chen M.Y., Liu H.H., Lien S.P., Yueh A., Hsiao K.N., Lai L.W., Liu F.C., Chong P., Chen H.W. A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect. 2009, 2:288-295.
49. Li S., Peng L., Zhao W., Zhong H., Zhang F., Yan Z., Cao H. Synthetic peptides containing B- and T-cell epitope of dengue virus-2 E domain III provoked B- and T-cell responses. Vaccine 2011, 29(20):3695-3702.
50. Li X., Yang X., Jiang Y., Liu J. A novel HBV DNA vaccine based on T cell epitopes and its potential therapeutic effect in HBV transgenic mice. Int. Immunol. 2005, 10:1293-1302.
51. Libraty D.H., Nisalak A., Endy T.P., Suntayakorn S., Vaughn D.W., Innis B.L. Clinical and immunological risk factors for severe disease in Japanese encephalitis. Trans. R. Soc. Trop. Med. Hyg. 2002, 96(2):173-178.
52. Lin C.W., Liu K., Huang H.D., Chen W.J. Protective immunity of E. coli-synthesized NS1 protein of Japanese encephalitis virus. Biotechnol. Lett. 2008, 30(2):205-214.
53. Lin X., Zhao J., Qian J., Mao Y., Pan J., Li L., Peng H., Luo Y., Yan J. Identification of immunodominant B- and T-cell combined epitopes in outer membrane lipoproteins LipL32 and LipL21 of Leptospira interrogans. Clin. Vaccine Immunol. 2010, 17(5):778-783.
54. Livingston B., Crimi C., Newman M., Higashimoto Y., Appella E., Sidney J., Sette A. A rational strategy to design multiepitope immunogens based on multiple Th lymphocyte epitopes. J. Immunol. 2004, 168(11):5499-5506.
55. Livingston B.D., Newman M., Crimi C., McKinney D., Chesnut R., Sette A. Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. Vaccine 2001, 19(32):4652-4660.
56. Löwenadler B., Lycke N., Svanholm C., Svennerholm A.M., Krook K., Gidlund M. T and B cell responses to chimeric proteins containing heterologous T helper epitopes inserted at different positions. Mol. Immunol. 1992, 10:1185-1190.
57. Martin P., Simon B., Lone Y.C., Chatel L., Barry R., Inchauspé G., Fournillier A.A. Vector-based minigene vaccine approach results in strong induction of T-cell responses specific of hepatitis C virus. Vaccine 2008, 26(20):2471-2481.
58. Memarnejadian A., Roohvand F., Arashkia A., Rafati S., Shokrgozar M.A. Polytope DNA vaccine development against hepatitis C virus: a streamlined approach from in silico design to in vitro and primary in vivo analyses in BALB/c mice. Protein Pept. Lett. 2009, 16(7):842-850.
59. Moeini H., Omar A.R., Rahim R.A., Yusoff K. Improving the potency of DNA vaccine against chicken anemia virus (CAV) by fusing VP1 protein of CAV to Marek's Disease Virus (MDV) type-1 VP22 protein. Virol. J. 2011, 8:119-126.
60. Paul S., Piontkivska H. Frequent associations between CTL and T-helper epitopes in HIV-1 genomes and implications for multi-epitope vaccine designs. BMC Microbiol. 2010, 10:212-227.
61. Pierson T.C., Diamond M.S. Molecular mechanisms of antibody-mediated neutralization of flavivirus infection. Expert Rev. Mol. Med. 2008, 12:10-12.
62. Pontarollo R.A., Babiuk L.A., Hecker R., Van Drunen Little Van Den Hurk S. Augmentation of cellular immune responses to bovine herpesvirus-1 glycoprotein D by vaccination with CpG-enhanced plasmid vectors. J. Gen. Virol. 2002, 83(Pt 12):2973-2981.
63. Rinaudo C.D., Telford J.L., Rappuoli R., Seib K.L. Vaccinology in the genome era. J. Clin. Invest. 2009, 119(9):2515-2525.
64. Roehrig J.T., Johnson A.J., Hunt A.R., Beaty B.J., Mathews J.H. Enhancement 883 of the antibody response to flavivirus B-cell epitopes by using homologous or 884 heterologous T-cell epitopes. J. Virol. 1992, 66(6):3385-3390.
65. Rueda P., Morón G., Sarraseca J., Leclerc C., Casal J.I. Influence of flanking sequences on presentation efficiency of a CD8+ cytotoxic T-cell epitope delivered by parvovirus-like particles. J. Gen. Virol. 2004, 85(Pt 3):563-572.
66. Sapkal G.N., Wairagkar N.S., Ayachit V.M., Bondre V.P., Gore M.M. Detection and isolation of Japanese encephalitis virus from blood clots collected during the acute phase of infection. Am. J. Trop. Med. Hyg. 2007, 77(6):1139-1145.
67. Scott W.R.P., Hunenberger P.H., Tironi I.G., Mark A.E., Billeter S.R., Fennen J., Torda A.E., Huber T., Kruger P., van Gunsteren W.F. The GROMOS biomolecular simulation program package. J. Phys. Chem. A 1999, 103(19):3596-3607.
68. Sette A., Livingston B., McKinney D., Appella E., Fikes J., Sidney J., Newman M., Chesnut R. The development of multi-epitope vaccines: epitope identification, vaccine design and clinical evaluation. Biologicals 2001, 29(3-4):271-276.
69. Shirai M., Chen M., Arichi T., Masaki T., Nishioka M., Newman M., Nakazawa T., Feinstone S.M., Berzofsky J.A. Use of an intrinsic and extrinsic helper epitopes for in vivo induction of anti-hepatitis C virus cytotoxic T lymphocytes (CTL) with CTL epitope peptide vaccines. J. Infect. Dis. 1996, 173(1):24-31.
70. Suhrbier A. Polytope vaccines for the codelivery of multiple CD8 T-cell epitopes. Expert Rev. Vaccines 2002, 1(2):207-213.
71. Tan L., Lu H., Zhang D., Tian M., Hu B., Wang Z., Jin N. Protection against H1N1 influenza challenge by a DNA vaccine expressing H3/H1 subtype hemagglutinin combined with MHC class II-restricted epitopes. Virol. J. 2010, 7(1):363-375.
72. Thomson S.A., Sherritt M.A., Medveczky J., Elliott S.L., Moss D.J., Fernando G.J., Brown L.E., Suhrbier A. Delivery of multiple CD8 cytotoxic T cell epitopes by DNA vaccination. J Immunol. 1998, 160(4):1717-1723.
73. Thomson S.A., Elliott S.L., Sherritt M.A., Sproat K.W., Coupar B.E., Scalzo A.A., Forbes C.A., Ladhams A.M., Mo X.Y., Tripp R.A., Doherty P.C., Moss D.J., Suhrbier A. Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. J. Immunol. 1996, 157(2):822-826.
74. Toes R.E., Hoeben R.C., van der Voort E.I., Ressing M.E., van der Eb A.J., Melief C.J., Offringa R. Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. Proc. Natl. Acad. Sci U.S.A.. 1997, 94(26):14660-14665.
75. van Gunsteren W.F., Berendsen H.J.C. Groningen Molecular Simulation (GROMOS) Library Manual 1987, BIOMOS B.V., Groningen.
76. Velders M.P., Weijzen S., Eiben G.L., Elmishad A.G., Kloetzel P.M., Higgins T., Ciccarelli R.B., Evans M., Man S., Smith L., Kast W.M. Defined flanking spacers and enhanced proteolysis is essential for eradication of established tumors by an epitope string DNA vaccine. J. Immunol. 2001, 166(9):5366-5373.
77. Wang F., He X.W., Jiang L., Ren D., He Y., Li D.A., Sun S.H. Enhanced immunogenicity of microencapsulated multiepitope DNA vaccine encoding T and B cell epitopes of foot-and-mouth disease virus in mice. Vaccine 2006, 24(12):2017-2026.
78. Wei J.C., Huang Y.Z., Zhong D.K., Kang L., Ishag H., Mao X., Cao R.B., Zhou B., Chen P.Y. Design and evaluation of a multi-epitope peptide against Japanese encephalitis virus infection in BALB/c mice. Biochem. Biophys. Res. Commun. 2010, 396(4):787-792.
79. Xie H.L., Wang Z., Cui S.J., Zhang C.F., Cui Y.D. The epitope of the VP1 protein of porcine parvovirus. Virol. J. 2010, 2010(7):161-166.
80. Zhang M.J., Wang M.J., Jiang S.Z., Ma W.Y. Passive protection of mice, goats, and monkeys against Japanese encephalitis with monoclonal antibodies. J. Med. Virol. 1989, 29(2):133-138.